Overview

Remimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation

Status:
Not yet recruiting

Trial end date:
2024-06-30

Target enrollment:
0

Participant gender:
All

Summary

Sedation is a component of the care of critically ill patients who are undergoing mechanical ventilation. Dexmedetomidine induces sedation while preserving a degree of arousability among patients in the intensive care unit (ICU), and its use has resulted in a shorter time to extubation, an increased number of days free from coma or delirium, a reduced incidence of agitated delirium, prevention of delirium, and lower mortality than other agents administered in certain populations. Hypotension and bradycardia are common side effects, which is lethal for the patients with persistent or severe hemodynamic instability. The pharmacological properties of rimazolom suggest that it is an ideal sedative drug for critically ill patients, but there is no relevant clinical research to confirm it. Therefore, this study mainly discusses the efficacy and safety of remidazolam in ICU patients with mechanical ventilation, so as to provide theoretical basis for individualized sedation treatment of patients with mechanical ventilation.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Tianjin Nankai Hospital

Treatments:

Dexmedetomidine

Criteria

Inclusion Criteria:

The main inclusion criteria are 18 years old or above, invasive mechanical ventilation is
required, and the clinical need is mild to moderate Sedated (RASS score 0 to -3) patients.

Exclusion Criteria:

1. Refuse to participate in this study

2. Patients with severe bradycardia (HR<50 bpm)

3. Patients who is pregnancy

4. Patients with brain injury or neurosurgery

5. Patients receiving sedation for treatment indications (such as epilepsy), not to
tolerate a ventilator.

6. Patients receiving any study medication within 30 days